Abstract:
We derive constrained Bayesian D-optimal designs for efficient estimation in phase I clinical trials with binary responses on a continuous dose space. The constraint is based on ethical considerations that patients cannot be assigned to highly toxic doses. We find that a naive restriction on the dose space, requiring patients to be assigned below the mean of a quantile, is about as effective as the more computationally intensive constrained designs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Babb, J., Rogatko, A., and Zacks, S. (1998). Cancer phase I clinical tials: Efficient dose escalation with overdose controls.Statistics in Medicine,17 1103–1120.
Chaloner, K. and Larntz, K. (1989). Optimal Bayesian Design Applied to Logistic Regression Experiments. Journal of Statistical Planning and Inference,21 191–208.
Clyde, M. and Chaloner, K. (1996). The equivalence of constrained and weighted designs in multiple objective problems. Journal of the American Statistical Association,91 1236–1244.
Durham, S.D. Flournoy, N. (1994). Random walks for quantile estimation. In: Gupta, S.S. and Berger, J.O. (eds.), Statistical Decision Theory and Related Topics V. Springer, New York, 467–476.
Fedorov, V.V. (1992). Optimal Design Construction With Constraints II. School of Statistics, University of Minnesota (technical report 575).
Haines, L.M. (1998). Optimal design for neural networks. In: Flournoy, N., Rosenberger, W.F., and Wong, W.K. (eds.), New Developments and Applications in Experimental Design, Institute of Mathematical Statistics, Hayward, 152–162.
Mats, V.A., Rosenberger, W.F., and Flournoy, N. (1998). Restricted optimality for phase I clinical trials. In: Flournoy, N., Rosenberger, W.F., and Wong, W.K. (eds.), New Developments and Applications in Experimental Design, Institute of Mathematical Statistics, Hayward, 50–61.
O’Quigley, J., Pepe, M., and Fisher, L. (1990). Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics, 46 33–48.
Perevozskaya, I. (1999). Optimal Design for Quantile Estimation With Application to Phase I Clinical Trials. University of Maryland Graduate School, Baltimore (doctoral thesis).
Schacter, L., Birkhofer, M., Carter, S., Canetta, R., Hellmann, S., Onetto, N., Weil, C., Winograd, B., and Rozencweig, M. (1997). Anticancer drugs. In: O’Grady, J. and Joubert, P.H. (eds.), Handbookof Phase I/II Clinical Trials. CRC Press, Boca Raton, 523–534.
Simon, R., Freidlin, B., Rubinstein, L., Arbuck, S. G., Collins, J. and Christian, M.C. (1997). Accelerated titration designs for phase I clinical trials in oncology.Journal of the National Cancer Institute 89 1138–1147.
Sitter, R.R. and Wu, C.F.J. (1999). Two-stage design of quantal response studiesBiometrics 55 396–402.
Whittle, P. (1973). Some general points in the theory of optimal experimental design. Journal of the Royal Statistical Society,B35 123–130.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Rosenberger, W.F., Haines, L.M., Perevozskaya, I. (2001). Constrained Bayesian Optimal Designs for Phase I Clinical Trials: Continuous Dose Space. In: Atkinson, A.C., Hackl, P., Müller, W.G. (eds) mODa 6 — Advances in Model-Oriented Design and Analysis. Contributions to Statistics. Physica, Heidelberg. https://doi.org/10.1007/978-3-642-57576-1_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-57576-1_25
Publisher Name: Physica, Heidelberg
Print ISBN: 978-3-7908-1400-2
Online ISBN: 978-3-642-57576-1
eBook Packages: Springer Book Archive